MONTREAL, March 1st, 2019 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced it will present data indicating the beneficial impact of transaminase flares during therapy on achieving HBV functional cure at the 2019 EASL / AASLD HBV Endpoints Meeting to be held March 8th – 9th, 2019 in London, UK.
This analysis (to be presented on March 8th as poster P03-01) draws on the entire enrolled patient population from both the REP 301 (NCT02233075) and REP 401 (NCT02565719) studies and evaluates transaminase flares observed during REP 2139-based combination therapy and their impact on liver function. In addition, the impact of baseline and response parameters on the appearance of transaminase flares and their correlation with functional cure are also evaluated.
Additional presentations on March 8th and 9th will provide updated mechanistic data on REP 2139 and off-treatment responses in the ongoing REP 401 protocol.
Replicor’s presentations from the 2019 EASL / AASLD HBV Endpoints Meeting will be available on the company’s website following their disclosure at the meeting at www.replicor.com/science/conference-presentations. For further information about the 2019 EASL / AASLD HBV Endpoints Meeting visit: https://www.aasld.org/events-professional-development/easl-aasld-hbv-treatment-endpoints-workshop.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.